

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Health Group Limited
中國衛生集團有限公司

(Carrying on business in Hong Kong as CHG HS Limited)

(Incorporated in Bermuda with limited liability)

(Stock Code: 673)

**CLARIFICATION ANNOUNCEMENT ON INTERIM RESULTS
ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024**

Reference is made to the interim results announcement of China Health Group Limited (the “**Company**”) for the six months ended 30 September 2024 (the “**Interim Results Announcement**”). Capitalised terms used in this announcement have the same meanings as those defined in the Interim Results Announcement unless defined otherwise herein.

The Company noted that there are inadvertent errors in respect of certain financial period descriptions and the loss per share of the Company for the six months ended 30 September 2024 in both English and Chinese versions of the Interim Results Announcement. Therefore, the Company wishes to clarify the information as follows (with revisions underlined):

For English version of the Interim Results Announcement only:

1. Reference is made to the condensed consolidated statement of profit or loss and other comprehensive income on page 2 in English version of the Interim Results Announcement. The Company would like to clarify that the wordings should be “Six months ended 30 September” instead of “Six months ended 30 June”.
2. Reference is made to the condensed consolidated statement of changes in equity on page 7 in English version of the Interim Results Announcement. The Company would like to clarify that the wordings should be “For the six months ended 30 September 2024” instead of “For the six months ended 30 June 2024”.

For both English and Chinese versions of the Interim Results Announcement:

1. References are made to (i) “Revenue” and “Other income and other (losses)/gain, net” on page 11; (ii) “Finance costs” and “Income tax Expense” on page 12; and (iii) “Loss for the period” and “Loss per share” on page 13 in both English and Chinese versions of the Interim Results Announcement. The Company would like to clarify that the wordings should be “Six months ended 30 September” instead of “Six months ended 30 June”.
2. Reference is made to the condensed consolidated statement of profit or loss and other comprehensive income on page 3 in both English and Chinese versions of the Interim Results Announcement. The Company would like to clarify that amount of loss per share attributable to owners of the Company should be “(3.59)”HK cents instead of “(3.54)” HK cents.
3. Reference is made to “Loss per share” on page 13 in the both English and Chinese versions of Interim Results Announcement. The Company would like to clarify that (i) the wordings should be “Weighted average number of ordinary shares in issue during the period used in the basic loss per share calculation” instead of “Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation”; and (ii) the amount of weighted average number of ordinary shares in issue during the period used in the basic loss per share calculation should be “484,249” instead of “491,645”.

Save for the above clarifications, other contents of both English and Chinese versions of the Interim Results Announcement remain unchanged. The unaudited consolidated financial statements of the Company for the six months ended 30 September 2024 with the above amendments will be incorporated and disclosed in the Company’s interim report for the six months ended 30 September 2024, which will be published in due course in compliance with the Listing Rules.

By order of the Board
China Health Group Limited
Chung Ho

Executive Director and Chief Executive Officer

Hong Kong, 20 December 2024

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Zhang Fan (Chairman), Mr. Chung Ho and Mr. Xing Yong; two non-executive Directors, namely, Mr. Huang Lianhai and Mr. Wang Jingming; and three independent non-executive Directors, namely, Mr. Jiang Xuejun, Mr. Du Yanhua and Mr. Lai Liangquan.